Sociedad Americana de Hirudoterapia

Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition

Research article published in The EMBO journal (1990)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDesarrollo de fármacosGrtter MG et al. · The EMBO journal, 1990

Abstract

Thrombin is a serine protease that plays a central role in blood coagulation. It is inhibited by hirudin, a polypeptide of 65 amino acids, through the formation of a tight, noncovalent complex. Tetragonal crystals of the complex formed between human alpha-thrombin and recombinant hirudin (variant 1) have been grown and the crystal structure of this complex has been determined to a resolution of 2.95 A. This structure shows that hirudin inhibits thrombin by a previously unobserved mechanism. In contrast to other inhibitors of serine proteases, the specificity of hirudin is not due to interaction with the primary specificity pocket of thrombin, but rather through binding at sites both close to and distant from the active site. The carboxyl tail of hirudin (residues 48-65) wraps around thrombin along the putative fibrinogen secondary binding site. This long groove extends from the active site cleft and is flanked by the thrombin loops 35-39 and 70-80. Hirudin makes a number of ionic and hydrophobic interactions with thrombin in this area. Furthermore hirudin binds with its N-terminal three residues Val, Val, Tyr to the thrombin active site cleft. Val1 occupies the position P2 and Tyr3 approximately the position P3 of the synthetic inhibitor D-Phe-Pro-ArgCH2Cl. Thus the hirudin polypeptide chain runs in a direction opposite to that expected for fibrinogen and that observed for the substrate-like inhibitor D-Phe-Pro-ArgCH2Cl.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmino Acid SequenceBinding SitesComputer GraphicsCrystallizationHirudinsHumansModels, MolecularMolecular Sequence DataOligopeptidesProtein ConformationSerine Proteinase InhibitorsThrombin

Resumen

Thrombin is a serine protease that plays a central role in blood coagulation.

Por qué esto importa para la hirudoterapia

This study determined the crystal structure of the complex formed between human alpha-thrombin and recombinant hirudin (variant 1) at 2.95 Å resolution. The abstract describes hirudin as a 65-amino-acid polypeptide that inhibits thrombin through a novel mechanism: rather than engaging the primary specificity pocket, hirudin binds at sites both near and distant from the active site, with its C-terminal tail wrapping along the fibrinogen secondary binding site and its N-terminal residues occupying the active-site cleft. This structural work is relevant to understanding thrombin inhibition at a molecular level. However, the abstract does not mention leeches, leech saliva, or medicinal leeches, and this is a preclinical structural biology study with no direct application to live leech therapy.

Citación

Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition

Grtter MG et al. · The EMBO journal, 1990

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.